JENNIFER LEMAN: Open Payments
NPI 1518201466 · MEDIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,470 in 113 payments from 18 companies in 2025. Trend: 2023 $1,926 · 2024 $1,495 · 2025 $2,470
Food & beverage: $2,470
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $417 |
| Madrigal Pharmaceuticals | 5 | $370 |
| Janssen Biotech, Inc. | 18 | $325 |
| GENZYME CORPORATION | 9 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $258 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $155 |
| Phathom Pharmaceuticals, Inc. | 6 | $121 |
| Ardelyx, Inc. | 6 | $119 |
| Aimmune Therapeutics, Inc. | 3 | $95 |
| PFIZER INC. | 5 | $94 |
Products named: REZDIFFRA, TREMFYA, DUPIXENT, RINVOQ, ENTYVIO, XIFAXAN, VOQUEZNA, IBSRELA.
Industry payments across PA — which companies pay providers there.
